Hepatitis D: Clinical Trials

14 trials for Hepatitis D, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

14 completed. 14 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 214Completed 14

Follow Hepatitis D: new trials by email Literature Review of Hepatitis D trials Research Report on Hepatitis D

Trials (filtered) newest first · largest first

All 14 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Clinical Trial of Hepalatide for Injection in Patients With Chronic Hepatitis D
hepalatide - Hepatitis D
Phase 2CompletedShanghai HEP Pharmaceutical Co., Ltd.902024-12-112026-10-29
Study of Hepalatide in Chronic Hepatitis D(CHD) Patients
Hepalatide, Hepalatide Placebo - Chronic Hepatitis D Infection
Phase 2CompletedShanghai HEP Pharmaceutical Co., Ltd.232023-10-072024-04-24
A Study of JNJ-73763989 + Nucleos(t)Ide Analog in Participants Co-Infected With Hepatitis B and Hepatitis D Virus
JNJ-73763989, Placebo, Entecavir (ETV) monohydrate - Hepatitis D, Chronic
Phase 2CompletedJanssen Research & Development, LLC522020-09-172026-07-22
Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)
Bulevirtide, Peginterferon Alfa-2a (PEG-IFN alfa) - Chronic Hepatitis Delta
Phase 2CompletedGilead Sciences1752019-05-312024-10-08
Treatment of Chronic Delta Hepatitis With Lonafarnib, Ritonavir and Lambda Interferon
Peg-interferon lambda, Lonafarnib, Ritonavir - Liver Disease, Hepatitis D
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)262018-08-012021-12-14
A Study to Evaluate Pegylated Interferon Lambda Monotherapy in Patients With Chronic Hepatitis Delta Virus Infection
Peginterferon Lambda-1A - Hepatitis D, Chronic
Phase 2CompletedEIT Pharma, Inc.332016-10-192026-09-08
A Multicenter, Open-label, Randomized Clinical Study to Assess Efficacy and Safety of 3 Doses of Myrcludex B for 24 Weeks in Combination With Tenofovir Compared to Tenofovir Alone to Suppress HBV Replication in Patients With Chronic Hepatitis D
Myrcludex B, Myrcludex-B, Tenofovir - Chronic Hepatitis D Infection With Hepatitis B
Phase 2CompletedHepatera Ltd.1202016-02-162021-05-10
Titrating-Dose of Lonafarnib in Combination With Ritonavir
lonafarnib, Ritonavir - Chronic Delta Hepatitis
Phase 2CompletedEIT Pharma, Inc.152015-09-012026-09-25
Treatment of Chronic Delta Hepatitis With Lonafarnib and Ritonavir
Lonafarnib, Ritonavir, Placebo - Hepatitis D
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)222015-07-292018-09-25
Lonafarnib for Chronic Hepatitis D
Lonafarnib, Placebo - Hepatitis D
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)142011-12-012016-08-31
HIDIT II - PegIFN-alfa2a Plus Tenofovir in Chronic Delta Hepatitis
PEG-IFN alfa-2a, Tenofovir, PEG-IFN alfa-2a, placebo - Hepatitis D
Phase 2CompletedHepNet Study House, German Liverfoundation702009-06-012018-01-29
A Study of Peginterferon Alfa-2a With or Without Ribavirin in Participants With Chronic Hepatitis D (CHD)
Peginterferon alfa-2a, Ribavirin - Hepatitis D, Chronic
Phase 2CompletedHoffmann-La Roche122004-09-012016-07-15
Pegylated Interferon to Treat Chronic Hepatitis D
Peginterferon Alpha-2a - Hepatitis D
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)132001-08-012013-07-10
Lamivudine for Chronic Hepatitis B
Lamivudine - Chronic Hepatitis B, Chronic Hepatitis D
Phase 2CompletedNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)601995-09-012008-03-04

Narrower conditions

Hepatitis D, Chronic (7)  ·  Fibrosis (3)  ·  Hepatitis (2)  ·  Hepatitis, Chronic (2)  ·  Liver Diseases (2)  ·  Glomerulonephritis (1)  ·  Hepatitis B, Chronic (1)  ·  Polyarteritis Nodosa (1)

Broader conditions

Digestive System Diseases (14)  ·  Hepatitis, Viral, Human (14)  ·  Infections (14)  ·  RNA Virus Infections (14)  ·  Virus Diseases (14)  ·  Hepatitis (12)  ·  Liver Diseases (12)  ·  Pathologic Processes (10)  ·  Pathological Conditions, Signs and Symptoms (10)  ·  Chronic Disease (9)  ·  Disease Attributes (9)  ·  Hepatitis, Chronic (7)  ·  Arteritis (1)  ·  Blood-Borne Infections (1)

Interventions

lonafarnib (4)  ·  Ritonavir (3)  ·  Tenofovir (3)  ·  peginterferon alfa-2a (3)  ·  myrcludex-B (2)  ·  Lamivudine (1)  ·  Ribavirin (1)  ·  bulevirtide (1)  ·  entecavir (1)  ·  peginterferon lambda-1a (1)  ·  tenofovir alafenamide (1)

Sponsors

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) (5)  ·  EIT Pharma, Inc. (2)  ·  Shanghai HEP Pharmaceutical Co., Ltd. (2)  ·  Gilead Sciences (1)  ·  HepNet Study House, German Liverfoundation (1)  ·  Hepatera Ltd. (1)  ·  Hoffmann-La Roche (1)  ·  Janssen Research & Development, LLC (1)

Countries

United States (6)  ·  Germany (3)  ·  Russia (3)  ·  China (2)  ·  France (2)  ·  Italy (2)  ·  Mongolia (2)  ·  New Zealand (2)  ·  Romania (2)  ·  Australia (1)  ·  Brazil (1)  ·  Greece (1)  ·  Israel (1)  ·  Japan (1)  ·  Moldova (1)

Top investigators

Theo Heller, M.D. (3)  ·  Christopher Koh, M.D. (1)  ·  David Apelian, MD, PhD, MBA (1)  ·  Heiner Wedemeyer, MD, PhD (1)  ·  Heiner Wedemeyer, MD,PhD (1)  ·  Junqi Niu (1)  ·  Michael P. Manns, Prof. Dr. (1)  ·  Oyunbileg Janchiv (1)

Results publications

PMID 30664876, PMID 26189433, PMID 30516520, PMID 30833068, PMID 34048594, PMID 36113537, PMID 37120031, PMID 37787009, PMID 38340811, PMID 38842520, PMID 39648559, PMID 40087915, PMID 41317314

NIH funding

2019 (1), 2023 (1)